What is the difference between retatrutide and tirzepatide?

Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide is a triple GLP-1/GIP/glucagon agonist — adding glucagon receptor activation. The glucagon component increases energy expenditure (basal metabolic rate), which contributes to retatrutide's superior weight loss beyond what appetite suppression alone achieves.

Is retatrutide FDA-approved?

No — retatrutide is in Phase 3 trials (TRIUMPH program) as of 2026. Tirzepatide is FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). Retatrutide FDA approval is anticipated in 2026–2027 pending Phase 3 results.

Which is safer — retatrutide or tirzepatide?

Tirzepatide has more published safety data from Phase 3 trials and post-marketing surveillance. Retatrutide's safety profile from Phase 2 is favorable and similar to tirzepatide, but long-term data is limited. For research purposes, tirzepatide has a more established safety record.

What are the advantages of retatrutide over tirzepatide?

Retatrutide's key advantages are: greater weight loss (24.2% vs 22.5%), superior liver fat reduction (82% vs ~40%), and the additional glucagon-mediated increase in energy expenditure. The triple mechanism may also offer advantages for non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome.

✦Use code HEALTH for 20% off at Purgo Labs✦

Head-to-Head Comparison

Retatrutide vs Tirzepatide

Head-to-head comparison of Retatrutide and Tirzepatide for fat loss. Which triple vs dual agonist produces better results?

Retatrutide and Tirzepatide are both next-generation weight loss peptides, but Retatrutide adds a third receptor target — the glucagon receptor — on top of the GIP and GLP-1 targets shared with Tirzepatide. This makes Retatrutide the most potent fat loss peptide in clinical trials, but also the most aggressive in terms of side effects.

Our Verdict

Winner: Retatrutide (fat loss) / Tirzepatide (tolerability)

Retatrutide wins on fat loss — up to 24% body weight reduction vs 15–22% for Tirzepatide in clinical trials. Tirzepatide wins on tolerability and established safety data. For researchers prioritizing maximum fat loss and willing to manage more aggressive titration, Retatrutide is the stronger compound. For those wanting proven results with a more established safety profile, Tirzepatide is the better choice.

Pathway Comparison Diagram

The glucagon receptor (GcgR) is the differentiating mechanism: Retatrutide's triple agonism drives additional energy expenditure beyond Tirzepatide's dual GLP-1R/GIPR activation.

Retatrutide vs Tirzepatide mechanism comparison showing GLP-1R+GIPR+GcgR triple agonist vs GLP-1R+GIPR dual agonist

What the cited studies used

One row per compound: the amount and schedule administered in a specific indexed study, who received it, and the paper. These are reports of what was done in that study, not recommendations, and several are animal or single-dose studies. Where no indexed human regimen exists we say so rather than print a number. Community "stacks" and cycle schedules are not reproduced on this site.

Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.

Compound	Regimen in the study	Population	Source
Retatrutide	1, 4, 8 or 12 mg subcutaneous once weekly for 48 weeks (initial doses 2–4 mg in the higher arms) Phase 2; the phase 3 TRIUMPH programme had not reported at the time of writing.	Adults with BMI ≥30 (or 27–30 with a weight-related condition) — phase 2	PMID 37366315 Jastreboff et al., N Engl J Med 2023
Tirzepatide	5, 10 or 15 mg subcutaneous once weekly for 72 weeks, including a 20-week escalation	2,539 adults with BMI ≥30 (or ≥27 with a complication), no diabetes — SURMOUNT-1	PMID 35658024 Jastreboff et al., N Engl J Med 2022

Retatrutide vs Tirzepatide: Side-by-Side

Category	Retatrutide	Tirzepatide
Receptor Targets	GIP + GLP-1 + Glucagon (triple agonist)	GIP + GLP-1 (dual agonist)
Fat Loss (Clinical)	Up to 24% body weight at 48 weeks	15–22% body weight at 72 weeks
Side Effects	More intense GI effects, especially early	Moderate GI effects, well-characterized
Half-life	~6 days (once weekly)	~5 days (once weekly)
Starting Dose	0.5–1mg/week	2.5mg/week
FDA Approval	Phase 3 trials (not yet approved)	Approved (Mounjaro/Zepbound)
Safety Data	Limited long-term data	Extensive clinical trial data
Best For	Maximum fat loss, aggressive protocols	Proven fat loss with established safety

Source Both Peptides at Purgo Labs

Purgo Labs carries research-grade Retatrutide and Tirzepatide with third-party COAs. Use code HEALTH for 20% off.

Visit Purgo Labs

Frequently Asked Questions

Is Retatrutide stronger than Tirzepatide?

Yes — Retatrutide produces greater fat loss (up to 24% vs 15–22%) due to the added glucagon receptor agonism, which directly promotes lipolysis beyond what GLP-1 alone achieves.

Can I switch from Tirzepatide to Retatrutide?

Yes, but always restart titration from the lowest dose. Receptor sensitivity does not carry over between compounds — starting Retatrutide at an equivalent Tirzepatide dose will cause significant GI side effects.

Which has more side effects?

Retatrutide tends to have more intense early GI side effects (nausea, vomiting) due to the glucagon component. Slow titration starting at 0.5–1mg/week minimizes this significantly.